GSK at ASH 2023
GSK will present its latest research advancements in blood cancers at the American Society of Hematology (ASH) 2023 Annual Meeting and Exposition. GSK’s data presentations, spanning both our myelofibrosis and multiple myeloma clinical trial programmes, demonstrate our ongoing commitment to improving outcomes for patients through the development of transformational medicines.
Multiple myeloma - Cindy's story
Cindy is turning “lemons into lemonade” and is motivated by her multiple myeloma diagnosis to advocate for others.
Myelofibrosis - Sole2Soul
Our commitment to the myelofibrosis community goes beyond our work to develop new therapies. We’re helping support patients and raise awareness for myelofibrosis. Learn more from the Sole2Soul for MPN hike.
Connecting with the myelofibrosis care partner and patient community
We recently launched Mapping Myelofibrosis, an initiative designed to provide information about this complex blood cancer and support the myelofibrosis patient community. This initiative will connect myelofibrosis patients and caregivers with educational tools, resources and stories to help navigate their journey, from the onset of symptoms through diagnosis and disease management.
Listen to our most recent episode, where we discuss myelofibrosis with a leader in the advocacy community.
Targeting a better future for multiple myeloma patients
GSK is driving progress for the multiple myeloma community by identifying and accelerating innovative ideas. Through our Target the Future Think Tank Challenge, GSK provides an £85,000 ($100,000) grant to the most innovative approach to address disparities multiple myeloma patients face. This year, our judging panel evaluated submissions from around the world. Learn more about the programme and the important work of our 2023 grantee on the Target the Future site.
Go behind the science
Discover how we’re uniting technology, science, and talent to get ahead of cancer and advance a new generation of cancer therapies.